Maria Rodil
Psychiatry · Miami, FLNPI 1740384122
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Alkermes, Inc. at 50.4% of the total. That places this record below the midpoint for psychiatry clinicians in FL, where the typical reported total is $420.
Across 5 payments — averaging $25.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$65
- Eyepoint US, Inc.$51
- Johnson & Johnson$13
Across 226 payments — averaging $20,123 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Axsome Therapeutics, Inc.$2.7M
- E.r. Squibb & Sons, L.L.C.$712K
- Janssen Research & Development, LLC$441K
- Teva Pharmaceuticals USA, Inc.$320K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$262K
- Avanir Pharmaceuticals, Inc.$100K
- plus $2K from 1 others
What the payments were for
- Food & beverage$129100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 3 | $65 |
| Eyepoint US, Inc. | 1 | $51 |
| Johnson & Johnson | 1 | $13 |
How this compares
$129 in reported general payments places this provider in the 30th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 24 | $48,629 |
| Clonazepam | 754 | $9,835 |
| TrintellixVortioxetine Hydrobromide | 15 | $7,439 |
| Alprazolam | 300 | $4,950 |
| Rivastigmine | 25 | $4,738 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 331 | $4,395 |
| Estazolam | 79 | $4,234 |
| Sertraline Hcl | 488 | $4,146 |
| Lorazepam | 348 | $4,021 |
| Temazepam | 359 | $3,341 |
| Bupropion XlBupropion Hcl | 128 | $2,857 |
| Quetiapine Fumarate | 223 | $2,542 |
| Aripiprazole | 64 | $2,477 |
| Mirtazapine | 159 | $2,417 |
| Doxepin Hcl | 77 | $1,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $13 | $48,62924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Miami
- Kenny PerezMiami$453K
- Erik CabreraMiami$357K
- Miguel FloresMiami$176K
- Pedro RodriguezMiami$96K
- John NewcomerMiami$96K
- Patricia JunqueraMiami$80K
- Marc AgroninMiami$66K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.